Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
311
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
All
Insights
Primers
New
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
China Traditional Chinese Medicine
•
30 Jun 2024 00:17
Weekly Deals Digest (30 Jun) - China TCM, Henlius, Midea RE, MMG, Aisin, Sanil, Shift Up
Last week, notable developments occurred in Event-Driven (China TCM, Henlius, Midea Real Estate, Best World) and ECM (Sanil, Shift Up, Aisin, MMG).
Arun George
Follow
518 Views
Share
bullish
•
China Traditional Chinese Medicine
•
29 Jun 2024 15:00
(Mostly) Asia-Pac M&A: TCM, Henlius Bio, Mideal Real Estate, Malaysia Airports, S Line, Best World
This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...
David Blennerhassett
Follow
636 Views
Share
bullish
•
Cross Asset Strategy
•
29 Jun 2024 08:10
The Heat Is On: News Flow and Sentiment in HONG KONG
China had positive flows into equity ETF's for June and mainland investors continued to direct money to Hong Kong stocks through the Stock Connect...
David Mudd
Follow
673 Views
Share
bearish
•
Cross Asset Strategy
•
27 Jun 2024 12:52
•
Syndicated
CX Daily: Consumers, Entrepreneurs Give Banks’ Retail Lending a Much-Needed Boost
Retail lending / In Depth: Consumers, entrepreneurs give banks’ retail lending a much-needed boost Despite market saturation stunting the credit...
Caixin Global
Follow
226 Views
Share
bearish
•
Shanghai Henlius Biotech
•
26 Jun 2024 08:55
Shanghai Henlius Biotech Privatization (2696.HK) - The Offer Price Is Disappointing
The ​Cancellation Price is 50% lower than Henlius's IPO price, causing losses for long-term players. Remaining public will provide good returns....
Xinyao (Criss) Wang
Follow
700 Views
Share
First
Previous
42
43
44
45
46
47
48
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.7
x